Aug 22 (Reuters) - Regeneron Pharmaceuticals on Tuesday said it had entered into a contract worth $326 million with a U.S. government agency for the development of next-generation antibody therapy for COVID-19 prevention. (Reporting by Pratik Jain in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,053 USD | +0.84% | +1.60% | +19.91% |
20/06 | Declaration of Voting Results by Regeneron Pharmaceuticals, Inc | CI |
18/06 | Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.91% | 11TCr | |
+15.19% | 12TCr | |
+8.24% | 2.36TCr | |
-19.80% | 2.04TCr | |
-16.19% | 1.65TCr | |
-13.45% | 1.64TCr | |
-44.35% | 1.56TCr | |
+66.67% | 1.52TCr | |
+2.13% | 1.35TCr | |
+119.39% | 1.1TCr |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron enters $326 mln pact with US to develop new COVID therapy